Low-dose selumetinib for children with plexiform neurofibromas
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This trial tests a low dose of a drug called selumetinib for children with NF1 who have plexiform neurofibromas that cannot be surgically removed. The goal is to see if this drug can help shrink or slow the growth of these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The child must be between 3 and 18 years old.
- They must have a confirmed diagnosis of NF1 (a genetic condition) and a plexiform neurofibroma (a type of nerve tumor) that cannot be removed safely with surgery.
- They must be able to swallow capsules and have normal liver, kidney, and heart function.
- They must not have had certain cancer treatments recently (like radiation within 6 weeks or other study drugs within 30 days).
- Parents or guardians must give written permission for the child to take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the drug selumetinib can prevent the growth of plexiform neurofibromas (nerve tumors) in young children with NF1. Children are first monitored with MRI scans, and if a tumor appears or grows, they may receive treatment.
This trial tests a combination of two targeted drugs (cabozantinib and selumetinib) for people with NF1 who have plexiform neurofibromas that are growing or causing significant problems. The goal is to see if this combination can shrink or slow the growth of these tumors.
This trial tests an experimental drug called HLX-1502 for people with NF1 who have a plexiform neurofibroma (a type of nerve tumor) that is growing or causing problems. It aims to see if the drug is safe and can shrink or stop the tumor from worsening.
This trial tests a study drug called mirdametinib in infants and toddlers who have neurofibromatosis type 1 (NF1) with plexiform neurofibromas (non-cancerous nerve tumors). The study aims to see if the drug can shrink or control these tumors, which may help prevent or reduce symptoms.
This trial tests a new pill (smeitinib) to shrink tumors caused by neurofibromatosis type 1 (NF1). It is for adults with NF1 who have tumors that cannot be removed by surgery, including those that press on the brain or spine.
This trial tests a capsule medication (smetinib) for people with type 1 neurofibromatosis (NF1) who have tumors that can be surgically removed but have not spread to vital areas like the brain or spine. The goal is to see if the drug can help shrink or control these tumors.
Hear when a new Plexiform Neurofibromas (PN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.